Table 1.
mRNA vaccines under clinical trials (up to 1 June 2023).
| Name of Product | ClinicalTrials.Gov Number | Payload | Disease | Phase | Route of Administration | Trial Status | Sponsor | Reference |
|---|---|---|---|---|---|---|---|---|
| Infectious diseases | ||||||||
| mRNA-1893 | NCT04917861 | Structural proteins of the Zika virus | Zika virus | 2 | I.M. | Active, recruiting | Moderna | [124] |
| mRNA-1647 | NCT04232280 | Six mRNA codings for pentamer viral antigen and gB protein of Cytomegalovirus | Cytomegalovirus infection | 2 | I.M. | Active, recruiting | Moderna | [125] |
| mRNA-1345 | NCT05127434 | The stabilized prefusion F protein | Respiratory syncytial virus | 2–3 | I.M. | Active, recruiting | Moderna | [126] |
| CVnCOV | NCT04652102 | SARS-CoV-2 | SARS-CoV-2 | 2–3 | I.M. | Active, not recruiting | CureVac | [127] |
| ARCT-021 | NCT04668339 | SARS-CoV-2 | SARS-CoV-2 | 2 | I.M. | Active, not recruiting | Arcturus | [128] |
| BNT162b2 | NCT04380701 | SARS-CoV-2 | SARS-CoV-2 | 1–2 | I.M. | Active, recruiting | BioNTech–Pfizer | [129] |
| mRNA-1273 | NCT04785144 | Codes for the full-length prefusion stabilized S protein of the SARS-CoV-2 B.1.351 variant. | SARS-CoV-2 B.1.351 variant | 2 | I.M. | Active, not recruiting | Moderna | [130] |
| Cancer | ||||||||
| BNT122 | NCT03815058 | 20 patient-specific neoantigens | Melanoma | 2 | I.V. | Active, recruiting | BioNTech– Genentech | [115] |
| mRNA-4157 | NCT03897881 | Encode up to 34 neoantigens | Melanoma | 2 | I.M. | Active, recruiting | Moderna–Merck | [51] |
| BNT111 | NCT04526899 | A mix of four melanoma-associated antigens | Melanoma | 2 | I.V. | Active, recruiting | BioNTech | [115] |
| CV9202 | NCT03164772 | NY-ESO-1, MAGE C1, MAGE C2, TPBG (5T4), survivin, MUC1 | Non-small cell lung cancer | 1–2 | I.D. | Active, not recruiting | CureVac, Ludwig Institute | [131] |
| BNT141 | NCT04683939 | Secreted IgG antibody | Cancer | 1–2 | I.V. | Not yet recruiting | BioNTech | [100] |
| BNT311/GEN1046 | NCT03917381 | Bispecific antibody PD-L1 × 4-1BB | Cancer | 1–2 | I.V. | Active, recruiting | Genmab–BioNTech | [121] |
| BNT312/GEN1042 | NCT04083599 | Bispecific antibody CD40 × 4-1BB | Solid tumors | 1–2 | I.V. | Active, recruiting | Genmab–BioNTech | [100] |
| BNT211 | NCT04503278 | CAR T for CLDN6 + tumor + mRNA for CLDN6 | CLDN6+ tumors | 1–2 | I.V. | Active, recruiting | BioNTech | [100] |
Abbreviations: I.M., Intramuscular; I.V., Intravenous; I.D., Intradermal.